KRAS mutation as a driver gene of advanced NSCLC, the data reported in the literature are not clear, and there is significant tumor heterogeneity, indicating that KRAS dependence is the main driver of poor prognosis (29–31). This evidence concerns the gene KRAS and non-small cell lung carcinoma.